Literature DB >> 23194

alpha-Adrenoceptors in the mouse vas deferens and their effects on its response to electrical stimulation.

I Marshall, P A Nasmyth, C G Nicholl, N B Shepperson.   

Abstract

1 Noradrenaline (ID50, 0.75 micrometer) and clonidine (ID50, 2.8 nM) produced a dose-related inhibition of the twitch response of the isolated vas deferens of the mouse to electrical stimulation, their effectiveness decreasing as frequency of stimulation increased from 0.2 to 16 hertz. 2 Phenylephrine (1.0--2.0 micrometer) produced a dose-related contraction of the mouse isolated vas deferens and potentiated the responses to field stimulation. 3 Yohimbine (10 nM) antagonized the inhibitory effects of noradrenaline and clonidine, but had no effect on the motor activity of phenylephrine. At a concentration of 128 nM yohimbine potentiated the twitch response by 110% at 1 Hz, but its effectiveness decreased with increasing frequency of stimulation up to 16 hertz. 4 Thymoxamine (0.3 micrometer) antagonized the effects of phenylephrine, but not those of clonidine. 5 From a consideration of the known characteristics of pre- and postsynaptic alpha-adrenoceptors, it is concluded that the inhibitory effect of noradrenaline is produced by stimulation of the former and the effects of phenylephrine by stimulation of the latter.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 23194      PMCID: PMC1667771          DOI: 10.1111/j.1476-5381.1978.tb07018.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  13 in total

1.  Evidence for an alpha- and beta2-receptor mediated inhibition of the twitch response in the guinea pig vas deferens by noradrenaline.

Authors:  U S von Euler; P Hedqvist
Journal:  Acta Physiol Scand       Date:  1975-04

2.  Pre- and postsynaptic components in effect of drugs with alpha adrenoceptor affinity.

Authors:  K Starke; T Endo; H D Taube
Journal:  Nature       Date:  1975-04-03       Impact factor: 49.962

3.  An inhibitory role for noradrenaline in the mouse vas deferens.

Authors:  D A Jenkins; I Marshall; P A Nasmyth
Journal:  Br J Pharmacol       Date:  1977-12       Impact factor: 8.739

4.  Preferential blockade of presynaptic alpha-adrenoceptors by yohimbine.

Authors:  K Starke; E Borowski; T Endo
Journal:  Eur J Pharmacol       Date:  1975-12       Impact factor: 4.432

5.  Effects of alpha-adrenoceptor agonists and antagonists on pre- and postsynaptically located alpha-adrenoceptors.

Authors:  G M Drew
Journal:  Eur J Pharmacol       Date:  1976-04       Impact factor: 4.432

6.  Evidence against adrenergic motor transmission in the guinea-pig vas deferens.

Authors:  N Ambache; M A Zar
Journal:  J Physiol       Date:  1971-07       Impact factor: 5.182

7.  Effect of duration and frequency of stimulation on the presynaptic inhibition by alpha-adrenoceptor stimulation of the adrenergic transmission.

Authors:  E S Vizi; G T Somogyi; P Hadházy; J Knoll
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

8.  Effect of morphine on adrenergic transmission in the mouse vas deferens. Assessment of agonist and antogonist potencies of narcotic analgesics.

Authors:  J Hughes; H W Kosterlitz; F M Leslie
Journal:  Br J Pharmacol       Date:  1975-03       Impact factor: 8.739

9.  Effect of flow-stop on noradrenaline release from normal spleens and spleens treated with cocaine, phentolamine or phenoxybenzamine.

Authors:  S M Kirpekar; M Puig
Journal:  Br J Pharmacol       Date:  1971-10       Impact factor: 8.739

10.  Role of the -adrenoceptor in regulating noradrenaline overflow by nerve stimulation.

Authors:  M A Enero; S Z Langer; R P Rothlin; F J Stefano
Journal:  Br J Pharmacol       Date:  1972-04       Impact factor: 8.739

View more
  15 in total

1.  Pre- and postsynaptic effects of yohimbine stereoisomers on noradrenergic transmission in the pulmonary artery of the rabbit.

Authors:  R Weitzell; T Tanaka; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-08       Impact factor: 3.000

2.  The effects of ketamine on noradrenergic transmission and the response to noradrenaline in rat smooth muscle [proceedings].

Authors:  A J Byrne; T E Healy; D R Tomlinson
Journal:  Br J Pharmacol       Date:  1979-11       Impact factor: 8.739

3.  Blockade of pre-synaptic alpha-adrenoceptors by metiamide [proceedings].

Authors:  O R Griffith; I Marshall; P A Nasmyth
Journal:  Br J Pharmacol       Date:  1978-11       Impact factor: 8.739

4.  A comparison of pre- and postsynaptic alpha-adrenergic effects of phenylephrine and tramazoline on blood vessels of the rabbit in vivo.

Authors:  A Steppeler; T Tanaka; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-10       Impact factor: 3.000

5.  The effects of release and depletion of endogenous noradrenaline on the transmission of impulses in the mouse vas deferens.

Authors:  I Marshall; P A Nasmyth; N B Shepperson
Journal:  Br J Pharmacol       Date:  1978-09       Impact factor: 8.739

6.  Dopamine inhibition of the twitch response of the mouse isolated vas deferens [proceedings].

Authors:  M J Hurst; I Marshall; P A Nasmyth
Journal:  Br J Pharmacol       Date:  1979-05       Impact factor: 8.739

7.  The effects of 4-aminopyridine on the isolated vas deferens and its effects on the inhibitory properties of adenosine, morphine, noradrenaline and gamma-aminobutyric acid.

Authors:  T W Stone
Journal:  Br J Pharmacol       Date:  1981-07       Impact factor: 8.739

8.  An electrophysiological study of presynaptic alpha-adrenoceptors in the vas deferens of the mouse.

Authors:  P Illes; K Starke
Journal:  Br J Pharmacol       Date:  1983-02       Impact factor: 8.739

9.  Stimulation-evoked release of [3H]-noradrenaline by 1, 10 or 100 pulses and its modification through presynaptic alpha 2-adrenoceptors.

Authors:  I Marshall
Journal:  Br J Pharmacol       Date:  1983-01       Impact factor: 8.739

10.  Evidence that the novel imidazoline compound FT005 is an alpha(2)-adrenoceptor agonist.

Authors:  Scott Slough; Gerald Guillaumet; Peter V Taberner
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.